🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

60,88 USD

Máx. histórico

89,55

116 días

Caída desde máximo

-32,02%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+1,52%

Cierre anterior

59,97

Rango de hoy

59,16 – 62,16

Volumen hoy

1.334.171

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,93%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,40 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 23 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
22/08/2025 49,42 51,00 48,97 50,57 +3,37% 4,11% 1.050.700
21/08/2025 48,74 49,23 48,27 48,92 +0,14% 1,97% 681.400
20/08/2025 49,38 49,99 48,09 48,85 -1,49% 3,85% 1.124.800
19/08/2025 48,98 54,24 48,97 49,59 -0,42% 10,76% 3.236.600
18/08/2025 48,60 49,94 47,94 49,80 +2,01% 4,13% 1.872.400
15/08/2025 48,86 49,22 47,97 48,82 +0,25% 2,56% 1.385.100
14/08/2025 47,58 49,45 47,35 48,70 +1,10% 4,41% 1.355.700
13/08/2025 45,75 49,10 45,43 48,17 +6,41% 8,03% 1.801.200
12/08/2025 43,32 45,99 43,32 45,27 +4,55% 6,16% 1.161.800
11/08/2025 45,43 46,43 43,18 43,30 -4,58% 7,16% 1.506.100
08/08/2025 45,00 48,36 45,00 45,38 -9,89% 7,46% 2.362.900
07/08/2025 51,92 51,97 50,18 50,36 -1,95% 3,46% 870.000
06/08/2025 51,30 51,38 50,18 51,36 +0,49% 2,33% 633.800
05/08/2025 52,06 52,45 50,70 51,11 -2,18% 3,37% 1.114.300
04/08/2025 52,33 52,86 51,35 52,25 +0,23% 2,89% 1.012.500
01/08/2025 51,80 52,40 50,67 52,13 +0,04% 3,35% 1.020.600
31/07/2025 50,69 52,70 50,36 52,11 +2,30% 4,62% 2.303.600
30/07/2025 49,33 51,65 49,33 50,94 +3,35% 4,70% 1.935.400
29/07/2025 47,50 50,49 46,49 49,29 +11,16% 8,42% 2.979.700
28/07/2025 44,82 45,37 44,15 44,34 -0,89% 2,72% 994.400
25/07/2025 45,69 45,80 44,42 44,74 -3,41% 3,02% 1.287.700
24/07/2025 46,83 47,61 46,28 46,32 -1,61% 2,84% 783.700
23/07/2025 46,46 47,10 45,83 47,08 +1,49% 2,73% 729.900
22/07/2025 47,96 48,23 45,91 46,39 -3,07% 4,83% 1.109.200
21/07/2025 47,66 48,69 47,17 47,86 +0,48% 3,19% 515.100
18/07/2025 48,88 49,09 47,23 47,63 -1,85% 3,81% 628.600
17/07/2025 48,35 49,45 48,26 48,53 +0,81% 2,46% 552.500
16/07/2025 47,83 48,66 47,28 48,14 +0,82% 2,89% 643.000
15/07/2025 49,44 49,90 47,60 47,75 -3,46% 4,65% 1.128.600
14/07/2025 48,67 50,34 48,60 49,46 +1,87% 3,59% 1.624.500